TAM
SLN

TFG Asset Management’s Silence Therapeutics SLN Stock Holding History

TFG Asset Management’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.29M Buy
+300,000
New +$2.11M 0.52% 30

Other funds holding SLN

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

TFG Asset Management's SLN Position: Q2 2026 in Review

TFG Asset Management increased its Silence Therapeutics (SLN) stake by 21% in Q2 2026, buying an estimated $943K and bringing the position to 764,256 shares worth $8.39M. The position accounts for 1.32% of the portfolio, ranked #17.

TFG Asset Management first reported a position in SLN in Q4 2025 and has held it in 3 quarters since. 72 funds tracked by Wall St. Rank hold SLN as of Q2 2026.

  • TFG Asset Management held 764,256 shares of Silence Therapeutics worth $8.39M as of Q2 2026.
  • TFG Asset Management bought 134,095 Silence Therapeutics shares in Q2 2026, an estimated $943K.
  • Silence Therapeutics made up 1.32% of TFG Asset Management's portfolio in Q2 2026, its #17 holding.
  • TFG Asset Management first reported a position in Silence Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 72 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2026.

Based on TFG Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.